Presystemic drug elimination

Annual Review of Pharmacology and Toxicology
P A Routledge, D G Shand


The presystemic elimination of a large number of compounds is clearly established and represents a common and unavoidable cause of reduced bioavailability. The liver, intestine, and lungs have been identified as potential organs contributing to this effect but only in the case of the liver are sufficient data available for comprehensive analysis. More information on intestinal and pulmonary metabolism is clearly needed. Simple methods of kinetic analysis already exist, however, to assess the relative importance of these organs in presystemic elimination, especially in relation to the pre- and postabsorptive types of elimination that may occur.


Jul 1, 1993·Journal of Clinical Pharmacology·J SombergS Ehrenpreis
Jan 1, 1993·European Journal of Clinical Pharmacology·M KotamäkiK E Laustiola
Jan 1, 1983·European Journal of Clinical Pharmacology·K K MidhaK Hall
Jan 1, 1984·European Journal of Clinical Pharmacology·P DorianV Khouw
Jan 1, 1981·Journal of Neural Transmission·T S Jensen, D F Smith
Jan 1, 1981·Pharmacology & Therapeutics·J P Griffin
Jan 1, 1988·Pharmacology & Therapeutics·A MelanderA McLean
May 1, 1996·Journal of Pain and Symptom Management·F M Ferrante
Jun 6, 2000·Advanced Drug Delivery Reviews·A K Mitra, R Krishnamoorthy
Nov 28, 2006·Nature Reviews. Cancer·Daniel W Nebert, Timothy P Dalton
Jul 9, 1981·The New England Journal of Medicine
Apr 1, 1993·Acta Anaesthesiologica Scandinavica·L Q ChristensenJ P Kampmann
Jun 1, 1981·Environmental Health Perspectives·D W Nebert
Dec 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·M SchwenkH Remmer
Apr 1, 1987·Journal of Pharmacological Methods·S Levine, A Saltzman
Jan 1, 1982·Virchows Archiv. B, Cell Pathology Including Molecular Pathology·R Lüllmann-Rauch, B Stoermer
Jan 1, 1984·Critical Reviews in Toxicology·B Clark, D A Smith
Aug 21, 2010·Critical Reviews in Toxicology·Douglas McGregor
May 4, 2011·Journal of Midwifery & Women's Health·Robin Webb Corbett, Laura Williford Owens
May 1, 1983·Toxicology and Applied Pharmacology·T N Thompson, C D Klaassen
Jun 30, 1982·Toxicology and Applied Pharmacology·T N Thompson, C D Klaassen
Sep 30, 1983·Toxicology and Applied Pharmacology·C LegraverendD W Nebert
Jan 1, 1988·American Heart Journal·C Dollery, P J Brennan
Mar 1, 1983·British Journal of Clinical Pharmacology·K K MidhaG McKay
Jan 1, 1984·Annals of the New York Academy of Sciences·P A Routledge
Apr 1, 1984·British Journal of Clinical Pharmacology·J B Houston, G Taylor
Jan 1, 1984·Biopharmaceutics & Drug Disposition·K K MidhaR M Roscoe
Jan 1, 1981·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R P BatzingerH Popper
Mar 21, 1981·British Medical Journal·M D Rawlins
May 1, 1983·The Journal of Pharmacy and Pharmacology·G Taylor, J B Houston
May 1, 1981·Critical Reviews in Toxicology·M E Andersen
May 1, 1980·The Journal of Pharmacy and Pharmacology·K F IlettD S Davies
Jan 1, 1989·Critical Reviews in Toxicology·D W Nebert
Apr 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Prajakti A Kothare, Cheryl L Zimmerman

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Landau-Kleffner Syndrome

Landau Kleffner syndrome (LKS), also called infantile acquired aphasia, acquired epileptic aphasia, or aphasia with convulsive disorder, is a rare childhood neurological syndrome characterized by the sudden or gradual development of aphasia (the inability to understand or express language) and an abnormal electroencephalogram. Discover the latest research on LKS here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.